Phase I Study of Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor, in Combination With Cisplatin in Patients With Refractory Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 08 Jun 2018
At a glance
- Drugs M 6620 (Primary) ; Veliparib (Primary) ; Cisplatin
- Indications Solid tumours
- Focus Adverse reactions
- 05 Jun 2018 Results (n=23) presented at the 54th Annual Meeting of the American Society of Clinical Oncology.
- 16 May 2018 According to the Merck KGaA media release, data from this trial will be presented at the American Society of Clinical Oncology Annual Meeting (ASCO) 2018.
- 28 Oct 2017 Planned End Date changed from 31 Dec 2017 to 31 Dec 2018.